The difference between an anomaly and a defect in product software can be confusing, but it is important to identify which is ...
Intas Pharmaceuticals was again in hot water with the US Food and Drug Administration (FDA) for a host of current good manufacturing practice (CGMP) violations, including manipulating particle counts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results